UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 6,759 Shares of Replimune Group, Inc. (NASDAQ:REPL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in Replimune Group, Inc. (NASDAQ:REPL) by 7.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 81,164 shares of the company’s stock after selling 6,759 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.12% of Replimune Group worth $890,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in REPL. Quest Partners LLC lifted its position in Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after acquiring an additional 3,150 shares in the last quarter. Algert Global LLC lifted its holdings in shares of Replimune Group by 5.4% during the second quarter. Algert Global LLC now owns 84,033 shares of the company’s stock valued at $756,000 after purchasing an additional 4,340 shares in the last quarter. Creative Planning boosted its position in shares of Replimune Group by 28.7% during the third quarter. Creative Planning now owns 21,047 shares of the company’s stock valued at $231,000 after buying an additional 4,699 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares in the last quarter. Finally, Los Angeles Capital Management LLC raised its position in Replimune Group by 8.1% in the 2nd quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock worth $646,000 after buying an additional 5,410 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Trading Up 3.0 %

Shares of REPL stock opened at $12.01 on Friday. The company has a market cap of $821.69 million, a price-to-earnings ratio of -3.94 and a beta of 1.26. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The firm has a fifty day moving average price of $12.23 and a 200-day moving average price of $10.64. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.07. As a group, equities analysts predict that Replimune Group, Inc. will post -2.91 earnings per share for the current year.

Insider Activity at Replimune Group

In other news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. BMO Capital Markets lifted their target price on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research report on Friday, November 22nd. JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a research note on Friday, November 22nd. Finally, Roth Mkm started coverage on Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $17.29.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.